
Screening at a dose of 0.1 mg/kg
12-14 carbon tail lengths were favorable
Screening at a dose of 1 mg/kg
Series 2
hit rate: 23% (10 out 43)
Screening at a dose of 1 mg/kg
Series 1
hit rate: 1.7% (1 out 60)
Relative FVII Protein Level
2.0
1.5
1.0
0.5
0.0
Control
K-E12
H-A12
Y-E12
G-O12
K-A12
R-E12
W-E12
H-E12
K-O12
H-O12
A-E12
I-E12
R-A12
K-A12
cVK-E12
PK-4K-E12
KK-A12
cKK-A12
cQK-E12
PK500-E12
PK1K-E12
cPK-E12
cKK-E12
cKT-E12
cAK-E12
cIK-E12
cKK-O12
cMK-E12
cEK-E12
cSK-E12
cDK-E12
cYK-E12
PK1K-O12
PK500-O12
cWK-E12
PK-4K-E12
KK-A12
cKK-A12
cQK-E12
PK500-E12
PK1K-E12
cPK-E12
cKK-E12
cKK-O12
cKK-E10
cKK-E12
cKK-E14
cKK-E16
cKK-A12
cKK-E12
PK-4K-E12
PK1K-E12
PK500-E12
cQK-E12

FIGURE 1


24 hours
Relative Fluorescence Level
100%
80%
60%
40%
20%
0%
Pancreas
Spleen
Liver
Fat
Kidneys
Uterus/Ovaries
Muscle
Heart
Lungs
Thymus
1 hour
Relative Fluorescence Level
100%
80%
60%
40%
20%
0%
Pancreas
Spleen
Liver
Fat
Kidneys
Uterus/Ovaries
Muscle
Heart
Lungs
Thymus
Free siRNA
cKK-E12

FIGURE 2


Relative Luciferase Level
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
AI AII B CI CII CIII E2 E3 E4 H --
cKK-E12 (50 ng)
CELLS

FIGURE 3


A
Relative Luciferase Expression
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Control
cKK-E12
cKK-A12
cKK-O12
Without ApoE
With ApoE
B
Untreated
cKK-E12
cKK-E12+ApoE
Visual uptake

FIGURE 4